Invitation: Sobi's Q3 2025 report

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call. The presentation can be followed livehere  or afterwards on sobi.com. The slides will be made available onsobi.com  before the conference call. To participate in the conference call, please use the following dial-in details: Sweden : +46 8 5051 0031United Kingdom : +44 207 107 06 13United States : +1 631 570 56 13 For other countries,...

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.

To participate in the conference call, please use the following dial-in details:

Sweden: +46 8 5051 0031
United Kingdom: +44 207 107 06 13
United States: +1 631 570 56 13

For other countries, please find the details here.

Sobi®

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

Gerard Tobin
Head of Investor Relations

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/invitation--sobi-s-q3-2025-report,c4246167

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-sobis-q3-2025-report-302578256.html